Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SHR-A1921 |
Synonyms | |
Therapy Description |
SHR-A1921 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TROP2 conjugated to a DNA topoisomerase I inhibitor, which potentially induces tumor cell killing and and inhibits growth of tumors expressing TROP2 (Cancer Res (2023) 83 (8_Supplement): LB030, Cancer Res (2023) 83 (8_Supplement): CT181). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SHR-A1921 | SHR A1921|SHRA1921|SHRA 1921|SHR-1921 | TROP2 Antibody 7 | SHR-A1921 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TROP2 conjugated to a DNA topoisomerase I inhibitor, which potentially induces tumor cell killing and and inhibits growth of tumors expressing TROP2 (Cancer Res (2023) 83 (8_Supplement): LB030, Cancer Res (2023) 83 (8_Supplement): CT181). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05594875 | Phase I | SHR-A1921 | A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors | Active, not recruiting | AUS | 0 |